The Latest Breakthroughs in mHSPC

CME Available: https://auau.auanet.org/node/43825

After participating in this CME activity, participants will be able to:

1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.

2.Implement current clinical guidelines for biomarker testing in mHSPC.

3.Explain the role of the PI3K/AKT pathway in prostate cancer biology.

4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.

5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.

Acknowledgements:

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.